FARXIGA in Endocrinology

NEW INDICATION: The first therapy approved in 20 years to help delay the worsening of CKD in patients at risk of progression, with and without T2D.1

Protect life: FARXIGA is proven to help protect your patients with CKD at risk of progression against worsening kidney function, ESKD, CV death, and hospitalization for heart failure—so they can live life.1

Micro- and macrovascular complications of T2D can develop and worsen over time, leading to death

Diabetes ComplicationsDiabetes Complications


CKD=chronic kidney disease; CV=cardiovascular; eCVD=established cardiovascular disease; ESKD=end-stage kidney disease; HFpEF=heart failure with preserved ejection fraction; HFrEF=heart failure with reduced ejection fraction; T2D=type 2 diabetes.

IMPORTANT SAFETY INFORMATION FOR FARXIGA